Journal
BIOMATERIALS
Volume 31, Issue 19, Pages 5237-5245Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2010.02.077
Keywords
Silica nanoparticle, MCM-41; Gene therapy; Growth factor; Tendon; Non viral gene delivery
Funding
- AFM (Association Francaise contre les Myopathies)
- French National Research Agency (ANR) [ANR-05-BLAN-0164]
- Agence Nationale de la Recherche (ANR) [ANR-05-BLAN-0164] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
We report the ability of amino- and carboxyl-modified MCM-41 mesoporous silica nanoparticles (MSN) to deliver gene in vivo in rat Achilles tendons, despite their inefficiency to transfect primary tenocytes in culture. We show that luciferase activity lasted for at least 2 weeks in tendons injected with these MSN and a plasmid DNA (pDNA) encoding the luciferase reporter gene. By contrast, in tendons injected with naked plasmid, the luciferase expression decreased as a function of time and became hardly detectable after 2 weeks. Interestingly, there were neither signs of inflammation nor necrosis in tendon, kidney, heart and liver of rat weekly injected with pDNA/MSN formulation during 1.5 months. Our main data concern the acceleration of Achilles tendons healing by PDGF-B gene transfer using MSN. Biomechanical properties and histological analyses clearly indicate that tendons treated with MSN and PDGF gene healed significantly faster than untreated tendons and those treated with pPDGE alone. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available